Kamada Ltd.
KMDAHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Sep 8, 2026
Scan Results
Daily timeframeKamada Ltd. manufactures and sells plasma-derived protein therapeutics. The $492.7M market capitalization puts KMDA squarely in small-cap range for its industry. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite.
Market Cap
$492.7M
Beta
0.14
P/E (TTM)
22.47
P/E (Fwd)
14.31
EPS (TTM)
$0.38
EPS (Fwd)
$0.60
ROE
8.4%
ROA
4.6%
Cash
$70.1M
Total Debt
$11.8M
Free CF
$15.5M
52W Change
19.4%
Annual Financials
Cash vs Debt
Where KMDA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, KMDA finished 8.25% above its 150-day moving average ($7.76) and 11.11% above its 200-day moving average ($7.56). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KMDA overbought or oversold?
At the September 3, 2026 close, KMDA's RSI(14) was 83.9, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Kamada Ltd. holds $70.1M in cash against $11.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $15.5M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 8.4% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.6% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $129.3M (2022) to $180.5M (2025), reflecting a 40% increase over the period.
With a beta below 0.7, Kamada Ltd. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Kamada Ltd. and its sector.